Endometrial cancer risk prediction including serum-based biomarkers: results from the EPIC cohort

International Journal of Cancer

Volumn 140, Issue 6, 2017, Pages 1317-1323

  Fortner, Renée T ^a   Hüsing, Anika ^a   Kühn, Tilman ^a   Konar, Meric ^a,b   Overvad, Kim ^c   Tjønneland, Anne ^d   Hansen, Louise ^d   Boutron Ruault, Marie Christine ^e,f,g   Severi, Gianluca ^e,f,g,h   Fournier, Agnès ^e,f,g   Boeing, Heiner ⁱ   Trichopoulou, Antonia ^j,k   Benetou, Vasiliki ^j,k   Orfanos, Philippos ^j,k   Masala, Giovanna ^l   Agnoli, Claudia ^m   Mattiello, Amalia ⁿ   Tumino, Rosario ^o   Sacerdote, Carlotta ^p   Bueno de Mesquita, H Bas ^q,r,s   Peeters, Petra H M ^r,t   Weiderpass, Elisabete ^u,v,w,x   Gram, Inger T ^u   Gavrilyuk, Oxana ^u,y   Quirós, J Ramón ^z   Maria Huerta, José ^aa,ab   Ardanaz, Eva ^ab,ac,ad   Larrañaga, Nerea ^ab,ae   Lujan Barroso, Leila ^af   Sánchez Cantalejo, Emilio ^ab,ag   Butt, Salma Tunå ^ah   Borgquist, Signe ^ai   Idahl, Annika ^aj   Lundin, Eva ^aj   Khaw, Kay Tee ^ak   Allen, Naomi E ^al   Rinaldi, Sabina ^am   Dossus, Laure ^am   Gunter, Marc ^am   Merritt, Melissa A ^r   Tzoulaki, Ioanna ^r   Riboli, Elio ^r   Kaaks, Rudolf ^a   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b HACETTEPE UNIVERSITY   (Turkey)

^c AARHUS UNIVERSITY   (Denmark)

^d DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^e INSERM   (France)

^f CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h Human Genetics Foundation   (Italy)

ⁱ GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^j HELLENIC HEALTH FOUNDATION   (Greece)

^k UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^l CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^m NATIONAL CANCER INSTITUTE   (Italy)

ⁿ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^o Civic MP Arezzo Hospital   (Italy)

^p CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^q NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^r IMPERIAL COLLEGE LONDON   (United Kingdom)

^s UNIVERSITY OF MALAYA   (Malaysia)

^t UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^u UNIVERSITY OF TROMSØ   (Norway)

^v CANCER REGISTRY OF NORWAY   (Norway)

^w KAROLINSKA INSTITUTE   (Sweden)

^x FOLKHÄLSAN RESEARCH CENTER   (Finland)

^y UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^z Public Health Dir   (Spain)

^aa DEPARTMENT OF EPIDEMIOLOGY   (Spain)

^ab CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^ac INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^ad IdiSNA Navarra Institute for Health Research   (Spain)

^ae Public Health Division of Gipuzkoa   (Spain)

^af BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^ag ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^ah LUND UNIVERSITY   (Sweden)

^ai LUND UNIVERSITY   (Sweden)

^aj UMEÅ UNIVERSITY   (Sweden)

^ak UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^al UNIVERSITY OF OXFORD   (United Kingdom)

^am INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

more..

Author keywords

adipokines; cytokines; endometrial cancer; growth factors; inflammatory markers; lipids; metabolic markers; prospective cohort; risk prediction; sex steroids

Indexed keywords

ADIPONECTIN; ANDROSTENEDIONE; C PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; ESTRADIOL; ESTRONE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; TESTOSTERONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; CYTOKINE; GLUCOSE BLOOD LEVEL; HORMONE; LIPID; PLASMA PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; ANALYSIS; BLOOD; CLINICAL TRIAL; COMORBIDITY; ENDOMETRIAL NEOPLASMS; EUROPE; FOLLOW UP; GLUCOSE BLOOD LEVEL; INCIDENCE; INFLAMMATION; METABOLIC SYNDROME X; MIDDLE AGED; MULTICENTER STUDY; QUESTIONNAIRE; RISK; SINGLE BLIND PROCEDURE;

ADULT; AGED; BIOMARKERS, TUMOR; BLOOD GLUCOSE; BLOOD PROTEINS; CASE-CONTROL STUDIES; COMORBIDITY; CYTOKINES; ENDOMETRIAL NEOPLASMS; EUROPE; FEMALE; FOLLOW-UP STUDIES; HORMONES; HUMANS; INCIDENCE; INFLAMMATION; LIPIDS; METABOLIC SYNDROME X; MIDDLE AGED; RISK; RISK ASSESSMENT; SINGLE-BLIND METHOD; SURVEYS AND QUESTIONNAIRES;

EID: 85010754999     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30560     Document Type: Article

References (20)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374–03.
2. Pfeiffer RM, Park Y, Kreimer AR, et al. Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies. PLoS Med 2013;10:e1001492.
3. Husing A, Dossus L, Ferrari P, et al. An epidemiological model for prediction of endometrial cancer risk in Europe. Eur J Epidemiol 2016;31:51–60.
4. Dossus L, Lukanova A, Rinaldi S, et al. Hormonal, metabolic, and inflammatory profiles and endometrial cancer risk within the EPIC cohort—a factor analysis. Am J Epidemiol 2013;177:787–99.
5. Allen NE, Key TJ, Dossus L, et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2008;15:485–97.
6. Cust AE, Allen NE, Rinaldi S, et al. Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition. Int J Cancer 2007;120:2656–64.
7. Cust AE, Kaaks R, Friedenreich C, et al. Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. J Clin Endocrinol Metab 2007;92:255–63.
8. Cust AE, Kaaks R, Friedenreich C, et al. Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2007;14:755–67.
9. Dossus L, Becker S, Rinaldi S, et al. Tumor necrosis factor (TNF)-alpha, soluble TNF receptors and endometrial cancer risk: the EPIC study. Int J Cancer 2011;129:2032–7.
10. Dossus L, Rinaldi S, Becker S, et al. Obesity, inflammatory markers, and endometrial cancer risk: a prospective case–control study. Endocr Relat Cancer 2010;17:1007–19.
11. Lukanova A, Lundin E, Micheli A, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 2004;108:425–32.
12. Wang T, Rohan TE, Gunter MJ, et al. A prospective study of inflammation markers and endometrial cancer risk in postmenopausal hormone nonusers. Cancer Epidemiol Biomarkers Prev 2011;20:971–7.
13. Stocks T, Bjorge T, Ulmer H, et al. Metabolic risk score and cancer risk: pooled analysis of seven cohorts. Int J Epidemiol 2015;44:1353–63.
14. Gunter MJ, Hoover DR, Yu H, et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 2008;17:921–9.
15. Riboli E. Nutrition and cancer: background and rationale of the European Prospective Investigation into Cancer and Nutrition (EPIC). Ann Oncol 1992;3:783–91.
16. Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002;5:1113–24.
17. Steyerberg EW. Clinical prediction models: a practical approach to development, validation, and updating. Springer, New York, 2009.
18. Pencina MJ, D'Agostino RB, Vasan RS. Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 2010;48:1703–11.
19. Pepe MS, Fan J, Seymour CW, et al. Biases introduced by choosing controls to match risk factors of cases in biomarker research. Clin Chem 2012;58:1242–51.
20. Pencina MJ. Caution is needed in the interpretation of added value of biomarkers analyzed in matched case control studies. Clin Chem 2012;58:1176.